Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. United Therapeutics Corp shares valued at $1,394,248 were sold by MAHON PAUL A on Apr 04 ’24. At $232.37 per share, MAHON PAUL A sold 6,000 shares. The insider’s holdings dropped to 36,710 shares worth approximately $8.59 million following the completion of this transaction.
Also, ROTHBLATT MARTINE A sold 15,000 shares, netting a total of over 3,441,093 in proceeds. Following the sale of shares at $229.41 each, the insider now holds 130 shares.
Before that, ROTHBLATT MARTINE A had sold 15,000 shares from its account. In a trade valued at $3,419,732, the CHAIRPERSON & CEO traded United Therapeutics Corp shares for $227.98 each. Upon closing the transaction, the insider’s holdings decreased to 15,000 shares, worth approximately $30410.9.
As published in a research note from Goldman on February 12, 2024, United Therapeutics Corp [UTHR] has been rated up from a Sell to a Neutral and the price target has been revised to $215 from $213. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in early February. As of December 08, 2023, Wells Fargo has initiated its “an Overweight” rating for UTHR. Earlier on December 06, 2022, UBS initiated its rating. Their recommendation was “a Buy” for UTHR stock.
Analyzing UTHR Stock Performance
During the last five days, there has been a drop of approximately -3.84%. Over the course of the year, United Therapeutics Corp shares have jumped approximately 6.39%. Shares of the company reached a 52-week high of $250.89 on 03/26/24 and a 52-week low of $208.62 on 02/08/24. A 50-day SMA is recorded $226.87, while a 200-day SMA reached $228.52. Nevertheless, trading volume fell to 0.52 million shares from 0.55 million shares the previous day.
Support And Resistance Levels for United Therapeutics Corp (UTHR)
According to the 24-hour chart, there is a support level at 230.74, which, if violated, would cause prices to drop to 227.56. In the upper region, resistance lies at 236.09. The next price resistance is at 238.26. RSI (Relative Strength Index) is 50.29 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -5.03, which suggests the price will decrease in the coming days. Percent R is at 57.77%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is United Therapeutics Corp subject to short interest?
Stocks of United Therapeutics Corp saw a sharp rise in short interest on Mar 15, 2024 jumping by 0.76 million shares to 1.92 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 1.16 million shares. A jump of 39.58% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.81 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.81.
